In the BioHarmony Drug Report Database
Onglyza (saxagliptin) is a small molecule pharmaceutical. Saxagliptin was first approved as Onglyza on 2009-07-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Onglyza’s patents are valid until 2028-11-30 (FDA).
Image (chem structure or protein)